Literature DB >> 20425012

Modern approach to managing vernal keratoconjunctivitis.

Sunil Kumar1, Nitin Gupta, Anthony J Vivian.   

Abstract

Vernal keratoconjunctivitis (VKC), an allergic inflammation of the conjunctiva affecting mainly children and adolescents, is categorized under the rubric of allergic conjunctivitis. Lack of uniform diagnostic and predefined staging criteria has been a bottleneck in formulating fixed guidelines to treat VKC. This lack of consensus among clinicians/researchers regarding diagnostic and grading standards has prevented us from making comparisons between the outcomes of different studies. To treat VKC, selection of a drug from many available options should be based on the duration and frequency of symptoms, grade and inflammation of giant papillae, and severity of corneal involvement. Consideration also should be given to the patient's specific needs. The basic tenet of treatment is optimal control of symptoms with a minimum of toxic side effects resulting from prolonged use of medication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425012     DOI: 10.1007/s11882-010-0101-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  42 in total

1.  Supra-tarsal injection of dexamethasone in the treatment of patients with refractory vernal keratoconjunctivitis.

Authors:  Mulu Lisanework
Journal:  Ethiop Med J       Date:  2003-01

2.  Topical cyclosporine in the management of shield ulcers.

Authors:  Altug Cetinkaya; Yonca Aydin Akova; Dilek Dursun; Aysel Pelit
Journal:  Cornea       Date:  2004-03       Impact factor: 2.651

3.  Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis.

Authors:  A G Secchi; M S Tognon; A Leonardi
Journal:  Am J Ophthalmol       Date:  1990-12-15       Impact factor: 5.258

4.  Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops.

Authors:  D BenEzra; N Matamoros; E Cohen
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

5.  Low dose mitomycin-C in severe vernal keratoconjunctivitis: a randomized prospective double blind study.

Authors:  Arun K Jain; Jaspreet Sukhija
Journal:  Indian J Ophthalmol       Date:  2006-06       Impact factor: 1.848

6.  Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.

Authors:  Işik Corum; Bariş Yeniad; Lale Közer Bilgin; Ridvan Ilhan
Journal:  J Ocul Pharmacol Ther       Date:  2005-10       Impact factor: 2.671

7.  Vernal keratoconjunctivitis in the black child and its response to therapy.

Authors:  E Dahan; R Appel
Journal:  Br J Ophthalmol       Date:  1983-10       Impact factor: 4.638

8.  Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.

Authors:  Haroon Ilyas; Charles B Slonim; Guy R Braswell; John R Favetta; Melvin Schulman
Journal:  Eye Contact Lens       Date:  2004-01       Impact factor: 2.018

9.  Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.

Authors:  Neri Pucci; Elio Novembre; Antonella Cianferoni; Enrico Lombardi; Roberto Bernardini; Roberto Caputo; Luciana Campa; Alberto Vierucci
Journal:  Ann Allergy Asthma Immunol       Date:  2002-09       Impact factor: 6.347

10.  Cromolyn effects on vernal keratoconjunctivitis in children.

Authors:  K F Tabbara; N T Arafat
Journal:  Arch Ophthalmol       Date:  1977-12
View more
  2 in total

Review 1.  An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.

Authors:  Susanna Esposito; Giulia Fior; Alessandro Mori; Silvia Osnaghi; Daniele Ghiglioni
Journal:  Paediatr Drugs       Date:  2016-10       Impact factor: 3.022

2.  Management of vernal keratoconjunctivitis.

Authors:  Andrea Leonardi
Journal:  Ophthalmol Ther       Date:  2013-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.